Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices 62803 

—Figure 2B, b-actin panel, representing 

b-actin expression in different cells 

with different treatments: 

D Left middle b-actin panel and right 

middle b-actin panel are duplicated by 

reusing the same source images with 

manipulation 

—Figures 3A and 3B, b-actin panels, 

representing b-actin expression in 

different cells with different 

treatments: 

D Left top b-actin panel in Figure 3A 

and left top b-actin panel in Figure 3B 

are identical 

D Right top b-actin panel in Figure 3A 

and left bottom b-actin panel in Figure 

3B are duplicated by reusing the same 

source images with manipulation 

D Right bottom b-actin panel in Figure 

3A and right bottom b-actin panel in 

Figure 3B are identical 

• Cancer Prev Res. 2011: 

—Figure 3A, representing expression of 

different proteins with different 

treatments: 

D Lane 1, aP2 panel, is falsified and/ 

or fabricated 

D Lanes 3 and 5, aP2 panel, and lanes 

1–6, 18S rRNA panel, are identical 

• Cancer Prev Res. 2012a: 

—Figure 4A, representing input 

expression treated with different 

doses of Zyflamend with or without 

17–AAG: 

D Lanes 1–5 are identical 

D Lanes 6–7 are identical 

—Figure 4B, representing input 

expression treated with different 

doses of carnosol with or without 17– 

AAG: 

D Lanes 1–5 are identical 

• Cancer Prev Res. 2012b: 

—Figure 2, representing expression of 

different proteins under different 

experimental conditions: 

D Lane 1, 15–PGDH panel in Figure 

2B and lanes 3–4, b-Actin panel in 

Figure 2E are duplicated by reusing a 

same source band with manipulation 

D Lane 2, b-Actin panel in Figure 2B 

and lane 1, Snail panel in Figure 2E are 

duplicated by reusing a same source 

band with manipulation 

D Lane 3, Snail panel in Figure 2G 

and lane 1, 15–PGDH panel in Figure 

2H are duplicated by reusing a same 

source band with manipulation 

D Lanes 1 and 2, b-Actin panel in 

Figure 2H are duplicated by reusing a 

same source band with manipulation 

D Lanes 1–3, b-Actin panel in Figure 

2J and lanes 1–2, b-Actin panel in 

Figure 2K are duplicated by reusing a 

same source band with manipulation 

—Figure 4E, b-Actin panel, representing 

b-actin expression in control and 

pioglitazone samples: 

D Lanes 1 and 2 are identical 

• Cancer Prev Res. 2013: 

—Figure 3, representing binding of 

nuclear protein from mammary glands 

of mice with different treatments: 

D Lanes 7–9 (first three empty lanes 

are counted also) and lanes 13–15 are 

identical 

• Cancer Prev Res. 2014: 

—Figures 5A and 5C, representing 

expression of different proteins with 

different treatments: 

D Lanes 2–3, CYP1A1 panel, and 

lanes 2–3, CYP1B1 panel, in Figure 5A 

and lane 3, CYP1B1 panel, in Figure 5C 

are duplicated by reusing a same source 

band with manipulation 

—Figure 5B, b-actin panel, representing 

b-actin expression in different cells 

with different treatments: 

D Lanes 2–4 are identical 

—Figure 5D, b-actin panel, representing 

b-actin expression in different cells 

with different treatments: 

D Lanes 1–4 are duplicated by reusing 

a same source band with manipulation 

• Cancer Prev Res. 2015: 

—Figure 3A, b-actin panel, representing 

b-actin expression in DLD–1 treated 

with different doses of PGE2: 

D Lanes 1, 3, and 5 are identical 

D Lanes 2 and 4 are identical 

Respondent entered into a Voluntary 

Exclusion Agreement (Agreement) and 

voluntarily agreed to the following: 

(1) Respondent will exclude himself 

voluntarily for a period of seven (7) 

years beginning on August 16, 2023 (the 

‘‘Exclusion Period’’), from any 

contracting or subcontracting with any 

agency of the United States Government 

and from eligibility for or involvement 

in nonprocurement or procurement 

transactions referred to as ‘‘covered 

transactions’’ in 2 CFR parts 180 and 

376 (collectively the ‘‘Debarment 

Regulations’’). 

(2) During the Exclusion Period, 

Respondent will exclude himself 

voluntarily from serving in any advisory 

or consultant capacity to PHS including, 

but not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee. 

Dated: September 8, 2023. 

Sheila Garrity, 

Director, Office of Research Integrity, Office 

of the Assistant Secretary for Health. 

[FR Doc. 2023–19780 Filed 9–12–23; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against 

Andrew Dannenberg, M.D. 

(Respondent), who was a Professor of 

Medicine, Department of Medicine, 

Weill Cornell Medical College (WCMC). 

Respondent engaged in research 

misconduct in research supported by 

U.S. Public Health Service (PHS) funds, 

specifically National Cancer Institute 

(NCI), National Institutes of Health 

(NIH), grants P01 CA077839, P01 

CA106451, R01 CA108773, R01 

CA154481, T32 CA009685, R25 

CA105012, and N01 CN43302, National 

Institute on Deafness and Other 

Communication Disorders (NIDCD), 

NIH, grant T32 DC000027, and National 

Center for Advancing Translational 

Sciences (NCATS), NIH, grant UL1 

TR000457. The administrative actions, 

including supervision for a period of 

seven (7) years, were implemented 

beginning on August 14, 2023, and are 

detailed below. 

FOR FURTHER INFORMATION CONTACT: 

Sheila Garrity, JD, MPH, MBA, Director, 

Office of Research Integrity, 1101 

Wootton Parkway, Suite 240, Rockville, 

MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Andrew Dannenberg, M.D., Weill 

Cornell Medical College (WCMC): Based 

on the report of an investigation 

conducted by WCMC and additional 

analysis conducted by ORI in its 

oversight review, ORI found that 

Andrew Dannenberg, former Professor 

of Medicine, Department of Medicine, 

WCMC, engaged in research misconduct 

in research supported by PHS funds, 

specifically NCI, NIH, grants P01 

CA077839, P01 CA106451, R01 

CA108773, R01 CA154481, T32 

CA009685, R25 CA105012, and N01 

CN43302, NIDCD, NIH, grant T32 

DC000027, and NCATS, NIH, grant UL1 

TR000457. 

ORI found that Respondent engaged 

in research misconduct by recklessly 

reporting falsified and/or fabricated data 

in the following twelve (12) published 

papers: 

• Increased levels of COX–2 and 

prostaglandin E2 contribute to elevated 

aromatase expression in inflamed breast 

tissue of obese women. Cancer Discov. 

2012 Apr;2(4):356–65. doi: 10.1158/ 

2159–8290.CD–11–0241 (hereafter 

referred to as ‘‘Cancer Discov. 2012’’). 

Retraction in: Cancer Discov. 2021 

May;11(5):1306. doi: 10.1158/2159– 

8290.CD–21–0224. 

• EP2 and EP4 receptors regulate 

aromatase expression in human 


ddrumheller on DSK120RN23PROD with NOTICES1
62804 Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices 

adipocytes and breast cancer cells. 

Evidence of a BRCA1 and p300 

exchange. J Biol Chem. 2008 Feb 

8;283(6):3433–44. doi: 10.1074/ 

jbc.M705409200 (hereafter referred to as 

‘‘J Biol Chem. 2008’’). Retraction in: J 

Biol Chem. 2020 Jan 3; 295(1):295. doi: 

10.1074/jbc.W119.012140. 

• HDAC6 modulates Hsp90 

chaperone activity and regulates 

activation of aryl hydrocarbon receptor 

signaling. J Biol Chem. 2009 Mar 20; 

284(12):7436–45. doi: 10.1074/ 

jbc.M808999200 (hereafter referred to as 

‘‘J Biol Chem. 2009’’). Retraction in: J 

Biol Chem. 2020 Jan 3; 295(1):297. doi: 

10.1074/jbc.W119.012142. 

• p53 protein regulates Hsp90 

ATPase activity and thereby Wnt 

signaling by modulating Aha1 

expression. J Biol Chem. 2014 Mar 

7;289(10):6513–25. doi: 10.1074/ 

jbc.M113.532523 (hereafter referred to 

as ‘‘J Biol Chem. 2014’’). Retraction in: 

J Biol Chem. 2020 Jan 3; 295(1):289. doi: 

10.1074/jbc.W119.012134. 

• Hsp90 and PKM2 drive the 

expression of aromatase in Li-Fraumeni 

syndrome breast adipose stromal cells. J 

Biol Chem. 2016 Jul 29;291(31):16011– 

23. doi: 10.1074/jbc.M115.698902 

(hereafter referred to as ‘‘J Biol Chem. 

2016’’). Retraction in: J Biol Chem. 2020 

Jan 3; 295(1):290. doi: 10.1074/ 

jbc.W119.012135. 

• Heat shock protein 90 inhibitors 

suppress aryl hydrocarbon receptormediated activation of CYP1A1 and 

CYP1B1 transcription and DNA adduct 

formation. Cancer Prev Res (Phila). 2008 

Nov;1(6):485–93. doi: 10.1158/1940– 

6207.CAPR–08–0149 (hereafter referred 

to as ‘‘Cancer Prev Res. 2008’’). 

Retraction in: Cancer Prev Res (Phila). 

2022 Jun 2;15(6):415. doi: 10.1158/ 

1940–6207.CAPR–22–0200. 

• Obesity is associated with 

inflammation and elevated aromatase 

expression in the mouse mammary 

gland. Cancer Prev Res (Phila). 2011 

Mar;4(3):329–46. doi: 10.1158/1940– 

6207.CAPR–10–0381 (hereafter referred 

to as ‘‘Cancer Prev Res. 2011’’). 

Retraction in: Cancer Prev Res (Phila). 

2022 Jun 2; 15(6):413. doi: 10.1158/ 

1940–6207.CAPR–22–0202. 

• Carnosol, a constituent of 

Zyflamend, inhibits aryl hydrocarbon 

receptor-mediated activation of CYP1A1 

and CYP1B1 transcription and 

mutagenesis. Cancer Prev Res (Phila). 

2012 Apr;5(4):593–602. doi: 10.1158/ 

1940–6207.CAPR–12–0002 (hereafter 

referred to as ‘‘Cancer Prev Res. 2012a’’). 

Retraction in: Cancer Prev Res (Phila). 

2022 Jun 2;15(6):412. doi: 10.1158/ 

1940–6207.CAPR–22–0203. 

• Pioglitazone, a PPARg agonist, 

suppresses CYP19 transcription: 

evidence for involvement of 15- 

hydroxyprostaglandin dehydrogenase 

and BRCA1. Cancer Prev Res (Phila). 

2012 Oct;5(10):1183–94. doi: 10.1158/ 

1940–6207.CAPR–12–0201 (hereafter 

referred to as ‘‘Cancer Prev Res. 

2012b’’). Retraction in: Cancer Prev Res 

(Phila). 2022 Jun 2;15(6):411. doi: 

10.1158/1940–6207.CAPR–22–0204. 

• Caloric restriction reverses obesityinduced mammary gland inflammation 

in mice. Cancer Prev Res (Phila). 2013 

Apr;6(4):282–9. doi: 10.1158/1940– 

6207.CAPR–12–0467 (hereafter referred 

to as ‘‘Cancer Prev Res. 2013’’). 

Retraction in: Cancer Prev Res (Phila). 

2022 Jun 2; 15(6):410. doi: 10.1158/ 

1940–6207.CAPR–22–0205. 

• p53 modulates Hsp90 ATPase 

activity and regulates aryl hydrocarbon 

receptor signaling. Cancer Prev Res 

(Phila). 2014 Jun;7(6):596–606. doi: 

10.1158/1940–6207.CAPR–14–0051 

(hereafter referred to as ‘‘Cancer Prev 

Res. 2014’’). Retraction in: Cancer Prev 

Res (Phila). 2022 Jun 2;15(6):408. doi: 

10.1158/1940–6207.CAPR–22–0207. 

• Id1 deficiency protects against 

tumor formation in Apc(Min/+) mice 

but not in a mouse model of colitisassociated colon cancer. Cancer Prev 

Res (Phila). 2015 Apr;8(4):303–11. doi: 

10.1158/1940–6207.CAPR–14–0411 

(hereafter referred to as ‘‘Cancer Prev 

Res. 2015’’). Retraction in: Cancer Prev 

Res (Phila). 2022 Jun 2;15(6):407. doi: 

10.1158/1940–6207.CAPR–22–0208. 

Respondent recklessly reported 

falsified and/or fabricated Western blot 

image data that were reused, with or 

without manipulation to conceal their 

similarities, and falsely relabeled as data 

representing different experiments or 

proteins in sixty (60) figure panels 

included in twelve (12) published 

papers. In the absence of reliable image 

and numerical data, the figures, 

statistical analyses, and related text also 

are false. 

Specifically, Respondent reported 

Western blot images that were reused 

from the same source and falsely 

relabeled to represent different proteins 

and/or experimental results in: 

• Cancer Discov. 2012: 

—Figure 2B, b-Actin panel, representing 

b-Actin expression in inflamed 

breast tissue with different levels of 

inflammation: 

D All lanes are duplicated by reusing 

a same source band with 

manipulation 

—Figure 4C, representing the expression 

of progesterone receptor (PR) and bActin in inflamed breast tissue with 

different levels of inflammation: 

D PR panel: Lanes 1, 2, and 14–16 are 

duplicated by reusing a same source 

band with manipulation; lanes 3, 6– 

9, 13, and 17 are duplicated by 

reusing a same source band with 

manipulation 

D b-Actin panel: All lanes are 

duplicated by reusing a same source 

band with manipulation 

—Figure 5H, b-Actin panel, representing 

b-Actin expression in macrophages 

with different treatments: 

D Lane 2 and lane 4 are identical 

• J Biol Chem. 2008: 

—Figure 2B, lanes 1–3, Aromatase 

panel, representing aromatase 

expression in adipocytes treated 

with PGE1 alcohol, and Figure 2E, 

lanes 2–4, Aromatase panel, 

representing aromatase expression 

in adipocytes treated with PGE2

with or without ONO, are 

duplicated by reusing the same 

source images with manipulation 

—Figure 3B, 18S rRNA panel, 

representing 18S rRNA expression 

in adipocytes with different 

treatments: 

D Lanes 2 and 6 are identical 

D Lanes 3 and 7 are identical 

—Figure 5A, 18S rRNA panel, 

representing 18S rRNA expression 

in adipocytes treated with different 

doses of PGE2: 

D Lanes 1 and 5 are identical 

D Lanes 2 and 6 are identical 

—Figure 5B, b-actin panel, representing 

b-actin expression in adipocytes 

treated with different doses of PGE2: 

D Lanes 1, 3, and 4 are identical 

—Figure 6D, BRCA1 and Aromatase 

panels, representing expression of 

both BRCA1 and aromatase in 

SKBR3 cells treated with different 

doses of PGE1 alcohol: 

D Lanes 3–4, BRCA1 panel and lanes 

1–2, Aromatase panel are 

duplicated by reusing the same 

source images with manipulation 

—Figure 5A, BRCA1 panel, representing 

BRCA1 expression in adipocytes 

treated with different doses of PGE2: 

D Lanes 3–6 are falsified and/or 

fabricated 

—Figure 5C, 18S rRNA panel, 

representing 18S rRNA expression 

in adipocytes treated with different 

doses of butaprost: 

D Entire 18S rRNA panel is falsified 

and/or fabricated 

—Figure 5E: 

D Lane 4, BRCA1 panel and lane 1, 

18S rRNA panel are identical 

—Figures 6C, 6D, 6E, and 6F: 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢ Figure 6C, lane 1, BRCA1 panel, 

representing BRCA1 expression in 

control sample without treatment of 

butaprost 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices 62805 

➢ Figure 6C, lane 3, Aromatase panel, 

representing aromatase expression 

with 0.25 mM butaprost treatment 

➢ Figure 6D, lane 1, BRCA1 panel, 

representing BRCA1 expression in 

control sample without treatment of 

PGE1 alcohol 

➢ Figure 6F, lane 1, BRCA1 panel, 

representing BRCA1 expression in 

control sample without treatment of 

PGE2 and ONO 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢ Figure 6C, lane 2, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with 0.10 mM 

butaprost 

➢ Figure 6D, lane 3, Aromatase panel, 

representing aromatase expression 

in sample treated with 0.25 mM 

PGE1 alcohol 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢ Figure 6C, lane 3, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with 0.25 mM 

butaprost 

➢Figure 6D, lane 3, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with 0.25 mM PGE1 

alcohol 

➢Figure 6D, lane 2, Aromatase panel, 

representing aromatase expression 

in sample treated with 0.10 mM 

PGE1 alcohol 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢Figure 6C, lane 4, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with 0.50 mM 

butaprost 

➢Figure 6C, lane 1, Aromatase panel, 

representing aromatase expression 

in control sample without treatment 

of butaprost 

➢Figure 6D, lane 1, Aromatase panel, 

representing aromatase expression 

in control sample without treatment 

of PGE1 alcohol 

➢Figure 6E, lane 2, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with PGE2 without 

AH6809 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢Figure 6C, lane 2, Aromatase panel, 

representing aromatase expression 

in sample treated with 0.10 mM 

butaprost 

➢Figure 6E, lane 3, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with PGE2 and 25 

mM AH6809 

➢Figure 6F, lane 2, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with PGE2 but 

without ONO 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢Figure 6C, lane 4, Aromatase panel, 

representing aromatase expression 

in sample treated with 0.50 mM 

butaprost 

➢Figure 6D, lane 2, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with 0.10 mM PGE1 

alcohol 

➢Figure 6E, lane 4, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with PGE2 and 50 

mM AH6809 

➢Figure 6F, lane 3, BRCA1 panel, 

representing BRCA1 expression in 

sample treated with PGE2 and 0.10 

mM ONO 

D Images used in the following figures 

are duplicated by reusing the same 

source images with manipulation: 

➢Figure 6D, 18S rRNA panel, 

representing 18S rRNA expression 

in samples treated with different 

doses of PGE1 alcohol 

➢Figure 6F, 18S rRNA panel, 

representing 18S rRNA expression 

in samples treated with different 

doses of PGE2 and ONO 

• J Biol Chem. 2009: 

—Figures 2A and 2B, b-actin panels, 

representing b-actin expression in 

KYSE450 cells and MSK-Leuk1 

cells, respectively: 

D The two panels are identical 

—Figure 3B, representing protein 

expression at two different time 

points: 

D Column 4, 1-hour panel, and 

column 2, 3-hour panel, are 

duplicated by reusing the same 

source images with resizing 

—Figure 6H, representing expression of 

different proteins with different 

treatments: 

D Column 1, Control group and 

column 3, Control siRNA group are 

identical 

—Figure 6I, representing expression of 

different proteins with different 

treatments: 

D Lanes 2 and 5, column 1 are 

identical 

D Lane 3, column 1 and lane 5, 

column 2 are identical 

—Figure 8G, Input panel, representing 

input protein expression in A549 

cells with different treatments: 

D Lanes 2 and 3 are identical 

—Figure 9B, Input panel, representing 

input protein expression in 

different samples: 

D Lanes 2 and 3 are identical 

—Figures 8E and 9D: 

D Images used in the following figures 

are duplicated by reusing a same 

source band with resizing: 

➢Figure 8E, lane 2, AhR panel, 

representing AhR expression in 

sample treated with B[a]P 

➢Figure 9D, lane 3, b-actin panel, 

representing b-actin expression in 

K/R sample treated with TS 

—Figure 9D, b-actin panel, representing 

b-actin expression under different 

experimental conditions: 

D Lane 1 is falsified and/or fabricated 

—Figure 9C, Input panel, representing 

input protein expression in K/A 

sample: 

D Lane 5 is falsified and/or fabricated 

—Figure S1A, p23 panel, representing 

p23 expression in MSK-Leuk1 cells 

and A549 cells: 

D Lanes 1 and 2 are identical 

—Figure S1C, XAP–2 panel, 

representing XAP–2 expression in 

control and sample treated with 

HDAC6 KD: 

D Lanes 1 and 2 are identical 

—Figure S1B, representing expression 

of different proteins in MSK-Leuk1 

cells with different treatments: 

D Lanes 3 and 4, Hsp90 panel are 

identical 

D Lanes 1 and 2, AhR panel are 

identical 

D Lanes 1 and 2, b-actin panel are 

identical 

D Lanes 3 and 4, b-actin panel are 

identical 

—Figure S1E, representing expression of 

different proteins in MSK-Leuk1 

cells with different treatments: 

D Lane 1, Hsp90 panel, and lanes 1 

and 2, HDAC6 panel, are identical 

D Lane 3, Hsp90 panel, and lane 3, 

XAP–2 panel, are identical 

—Figure S2, representing expression of 

different proteins in MSK-Leuk1 

cells with different treatments: 

D Last lane, IB AcK panel, and lanes 

3 and 5, IB HSP90 panel, are 

duplicated with resizing 

D Lane 4, IB AcK panel, and lanes 1, 

4, and 6, IB HSP90 panel, are 

duplicated with resizing 

D Lane 4, IB AcK panel, is falsified 

and/or fabricated 

• J Biol Chem. 2014: 

—Figure 1D, representing expression of 

different proteins treated with 

control or p53 siRNA: 

D Lane 1, p53 panel, and lanes 1 and 

2, b-actin panel, are duplicated by 

reusing a same source band with 

manipulation 

—Figure 2B, b-actin panel, representing 

b-actin expression in HCT–15 cells 

treated with different doses of CP– 

31398: 

D Lane 1 and lane 5 are identical 

D Lane 2 and lane 6 are identical 

—Figure 4K, p23 panel, representing 

p23 expression in samples treated 


ddrumheller on DSK120RN23PROD with NOTICES1
62806 Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices 

with different doses of CP–31398 in 

HCT–15 cells: 

D Lanes 2–4 are identical 

—Figures 4H, 4I, and 4L, b-actin panels, 

representing b-actin expression 

under different experimental 

conditions: 

D b-actin panels in Figures 4H and 4I, 

and lanes 3–4, b-actin panel in 

Figure 4L are duplicated by reusing 

the same source images with 

manipulation 

—Figures 4J, 4K, and 4L, representing 

expression of HOP (Figure 4J) and 

b-actin (Figures 4K and 4L) under 

different experimental conditions: 

D Lanes 1–2, HOP panel in Figure 4J, 

lanes 3–4, b-actin panel in Figure 

4K, and lanes 1–2, b-actin panel in 

Figure 4L are duplicated by reusing 

the same source images with 

manipulation 

—Figures 5A and 5B, b-actin panels, 

representing b-actin expression in 

both HCT–15 cells and EB–1 cells, 

are identical 

—Figure 5H, c-Myc panel and Naked-1 

panel, representing expression of cMyc and Naked-1 in EB–1 cells, are 

duplicated with resizing 

—Figures 10A and 10B, representing bactin (Figure 10A) and Aha1 (Figure 

10B) expression: 

D Lanes 2–3, b-actin panel in Figure 

10A and lanes 2–3, Aha1 panel in 

Figure 10B are duplicated with 

resizing 

• J Biol Chem. 2016: 

—Figures 1C and 7A, b-actin panels, 

representing b-actin expression in 

different cells: 

D Lanes 1–2, b-actin panel in Figure 

1C and lanes 2–3, b-actin panel in 

Figure 7A are duplicated by reusing 

the same source images with 

manipulation 

—Figure 5B, representing expression of 

different proteins with different 

treatments: 

D Lane 6, PKM2 panel, and lane 5, 

Hsp90 panel, are identical 

—Figure 5A, representing expression of 

different proteins with different 

treatments: 

D Lane 2, HIF–1a panel, and lane 1, 

b-actin panel, are identical 

• Cancer Prev Res. 2008: 

—Figure 2B, b-actin panel, representing 

b-actin expression in different cells 

with different treatments: 

D Left middle b-actin panel and right 

middle b-actin panel are duplicated 

by reusing the same source images 

with manipulation 

—Figures 3A and 3B, b-actin panels, 

representing b-actin expression in 

different cells with different 

treatments: 

D Left top b-actin panel in Figure 3A 

and left top b-actin panel in Figure 

3B are identical 

D Right top b-actin panel in Figure 3A 

and left bottom b-actin panel in 

Figure 3B are duplicated by reusing 

the same source images with 

manipulation 

D Right bottom b-actin panel in Figure 

3A and right bottom b-actin panel 

in Figure 3B are identical 

• Cancer Prev Res. 2011: 

—Figure 3A, representing expression of 

different proteins with different 

treatments: 

D Lane 1, aP2 panel, is falsified and/ 

or fabricated 

D Lanes 3 and 5, aP2 panel, and lanes 

1–6, 18S rRNA panel, are identical 

• Cancer Prev Res. 2012a: 

—Figure 4A, representing input 

expression treated with different 

doses of Zyflamend with or without 

17–AAG: 

D Lanes 1–5 are identical 

D Lanes 6–7 are identical 

—Figure 4B, representing input 

expression treated with different 

doses of carnosol with or without 

17–AAG: 

D Lanes 1–5 are identical 

• Cancer Prev Res. 2012b: 

—Figure 2, representing expression of 

different proteins under different 

experimental conditions: 

D Lane 1, 15–PGDH panel in Figure 

2B and lanes 3–4, b-Actin panel in 

Figure 2E are duplicated by reusing 

a same source band with 

manipulation 

D Lane 2, b-Actin panel in Figure 2B 

and lane 1, Snail panel in Figure 2E 

are duplicated by reusing a same 

source band with manipulation 

D Lane 3, Snail panel in Figure 2G 

and lane 1, 15–PGDH panel in 

Figure 2H are duplicated by reusing 

a same source band with 

manipulation 

D Lanes 1 and 2, b-Actin panel in 

Figure 2H are duplicated by reusing 

a same source band with 

manipulation 

D Lanes 1–3, b-Actin panel in Figure 

2J and lanes 1–2, b-Actin panel in 

Figure 2K are duplicated by reusing 

a same source band with 

manipulation 

—Figure 4E, b-Actin panel, representing 

b-actin expression in control and 

pioglitazone samples: 

D Lanes 1 and 2 are identical 

• Cancer Prev Res. 2013: 

—Figure 3, representing binding of 

nuclear protein from mammary 

glands of mice with different 

treatments: 

D Lanes 7–9 (first three empty lanes 

are counted also) and lanes 13–15 

are identical 

• Cancer Prev Res. 2014: 

—Figures 5A and 5C, representing 

expression of different proteins 

with different treatments: 

D Lanes 2–3, CYP1A1 panel, and 

lanes 2–3, CYP1B1 panel, in Figure 

5A and lane 3, CYP1B1 panel, in 

Figure 5C are duplicated by reusing 

a same source band with 

manipulation 

—Figure 5B, b-actin panel, representing 

b-actin expression in different cells 

with different treatments: 

D Lanes 2–4 are identical 

—Figure 5D, b-actin panel, representing 

b-actin expression in different cells 

with different treatments: 

D Lanes 1–4 are duplicated by reusing 

a same source band with 

manipulation 

• Cancer Prev Res. 2015: 

—Figure 3A, b-actin panel, representing 

b-actin expression in DLD–1 treated 

with different doses of PGE2: 

D Lanes 1, 3, and 5 are identical 

D Lanes 2 and 4 are identical 

Respondent entered into a Voluntary 

Settlement Agreement (Agreement) and 

voluntarily agreed to the following: 

(1) Respondent will have his research 

supervised for a period of seven (7) 

years beginning on August 14, 2023 (the 

‘‘Supervision Period’’). Prior to the 

submission of an application for PHS 

support for a research project on which 

Respondent’s participation is proposed 

and prior to Respondent’s participation 

in any capacity in PHS-supported 

research, Respondent will submit a plan 

for supervision of Respondent’s duties 

to ORI for approval. The supervision 

plan must be designed to ensure the 

integrity of Respondent’s research. 

Respondent will not participate in any 

PHS-supported research until such a 

supervision plan is approved by ORI. 

Respondent will comply with the 

agreed-upon supervision plan. 

(2) The requirements for Respondent’s 

supervision plan are as follows: 

i. A committee of 2 senior faculty 

members at the institution who are 

familiar with Respondent’s field of 

research, but not including 

Respondent’s supervisor or 

collaborators, will provide oversight and 

guidance for a period of seven (7) years 

from the effective date of the 

Agreement. The committee will review 

primary data from Respondent’s 

laboratory on a quarterly basis and 

submit a report to ORI at six (6) month 

intervals setting forth the committee 

meeting dates and Respondent’s 

compliance with appropriate research 

standards and confirming the integrity 

of Respondent’s research. 

ii. The committee will conduct an 

advance review of each application for 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices 62807 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved. The review will include a 

discussion with Respondent of the 

primary data represented in those 

documents and will include a 

certification to ORI that the data 

presented in the proposed application, 

report, manuscript, or abstract are 

supported by the research record. 

(3) During the Supervision Period, 

Respondent will ensure that any 

institution employing him submits, in 

conjunction with each application for 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported and not plagiarized 

in the application, report, manuscript, 

or abstract. 

(4) If no supervision plan is provided 

to ORI, Respondent will provide 

certification to ORI at the conclusion of 

the Supervision Period that his 

participation was not proposed on a 

research project for which an 

application for PHS support was 

submitted and that he has not 

participated in any capacity in PHSsupported research. 

(5) During the Supervision Period, 

Respondent will exclude himself 

voluntarily from serving in any advisory 

or consultant capacity to PHS including, 

but not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee. 

Dated: September 8, 2023. 

Sheila Garrity, 

Director, Office of Research Integrity, Office 

of the Assistant Secretary for Health. 

[FR Doc. 2023–19779 Filed 9–12–23; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Assessment of Potential Substance Abuse 

Treatment Medications in Nonhuman 

Primate Models. 

Date: October 26, 2023. 

Time: 12:00 p.m. to 1:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Soyoun Cho, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 594–9460, 

Soyoun.cho@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Accelerating the Pace of Drug Abuse 

Research Using Existing Data. 

Date: November 2, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Li Rebekah Feng, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Institute on Drug Abuse, 

NIH, 301 North Stonestreet Avenue, MSC 

6021, Bethesda, MD 20892, (301) 827–7245, 

rebekah.feng@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: September 7, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–19724 Filed 9–12–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory Eye 

Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The open 

session will be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting website (https://

videocast.nih.gov/watch=52408). 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The intramural programs 

and projects as well as the grant 

applications and/or contract proposals 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Eye Council. 

Date: October 13, 2023. 

Open: 8:30 a.m. to 3:00 p.m. 

Agenda: Presentation of the NEI Director’s 

report, discussion of NEI programs, and 

concept clearances. 

Place: National Eye Institute, 6700B 

Rockledge Drive, Bethesda, MD 20892 

Closed: 3:15 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Eye Institute, 6700B 

Rockledge Drive, Bethesda, MD 20892. 

Contact Person: Kathleen C. Anderson, 

Ph.D., Director, Division of Extramural 

Activities, National Eye Institute, 6700B 

Rockledge Drive, Room 3440, Bethesda, MD 

20892, (301) 451–2020, kanders1@

nei.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the contact person listed 

above before the meeting or within 15 days 

after the meeting. The statement should 

include the name, address, telephone number 

and when applicable, the business or 

professional affiliation of the interested 

person. 


ddrumheller on DSK120RN23PROD with NOTICES1